SCHEMBL30765686

SCHEMBL30765686

C[C@H](Nc1nccn(CC(=O)NCc2cc3cnccc3[nH]2)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.35
MAPK1 P28482 2/20 0.35
POLB P06746 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
USP2 O75604 1/20 0.33
F3 P13726 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
RECQL P46063 1/20 0.33
LMNA P02545 2/20 0.32
MASP2 O00187 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KDM4E B2RXH2 2/20 0.32
NAMPT P43490 1/20 0.32
RAB9A P51151 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765603 0.90 F2 (0.35) F2MAPK1POLBALDH1A1MAPT
SCHEMBL30765440 0.87 F7 (0.39) F2MAPK1F3
SCHEMBL30765497 0.87 POLB (0.36) F2MAPK1POLBALDH1A1MAPT
SCHEMBL30765753 0.85 F2 (0.34) F2MAPK1F3LMNA
SCHEMBL30765642 0.85 MAPK1 (0.35) F2MAPK1POLBALDH1A1USP2
SCHEMBL30765728 0.84 MAPK1 (0.38) F2MAPK1NAMPT
SCHEMBL30765543 0.84 ELANE (0.39) F2MAPK1F3
SCHEMBL30765625 0.84 F2 (0.36) F2MAPK1ALDH1A1MAPTUSP2
SCHEMBL30765870 0.83 F2 (0.35) F2MAPK1ALDH1A1MAPTUSP2
SCHEMBL30765871 0.83 F2 (0.36) F2MAPK1ALDH1A1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed